


Abstract

The present disclosure relates to a heterogeneous nuclear ribosomal protein A2B1 (hnRNPA2B1) hnRNPA2B1 agonist compound and an anti-tumor use thereof. Specifically, the present disclosure relates to a condensed cyclic compound as represented by formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate or a pharmaceutically acceptable salt thereof or a prodrug thereof, a composition and product comprising any one of the foregoing, and a use of the described substances as an hnRNPA2B1 agonist in the preparation of a product for tumor prevention and/or treatment. The present disclosure can be used for broad-spectrum tumor prevention and treatment, and has a wide application prospect.



[No figure]